• Seattle AVM Announces Second IND for AVM0703 for COVID-19, Influenza ARDS americanpharmaceuticalreview
    September 23, 2020
    AVM Biotechnology has received U.S. Food and Drug Administration (FDA) permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza ...
PharmaSources Customer Service